Context Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $31.9M | $22.7M | $17.8M | $7.1M | $3.8M |
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Interest expense | — | — | — | — | $64,240 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M |
| Balance Sheet | |||||
| Cash and equivalents | $66.0M | $94.4M | $14.4M | $35.5M | $49.6M |
| Current assets | $68.4M | $97.9M | $16.0M | $37.9M | $51.3M |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M |
| Current liabilities | $8.0M | $2.7M | $4.2M | $3.2M | $3.0M |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M |
| Stockholders' equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M |
| Depreciation and amortization | $16,251 | $10,881 | $12,044 | $9,268 | $0 |
| Stock-based compensation | $1.3M | $841,867 | $1.1M | $976,440 | $511,079 |
| Capital expenditure | $33,948 | $7,316 | $0 | $36,836 | $0 |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.6M | -$8.8M |
Shares outstanding 91.9M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.